Showing results (1521-1530 of 1,553) with videos related to
Sort By:
Pageof 156
Journal of the National Cancer Center|July 22, 2024
Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)Jianchun Duan, Wenfeng Fang, Hairong Xu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2023
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 TrialJianchun Duan, Lin Wu, Kunyu Yang, et al.Blood Advances|August 27, 2025
A mouse model for hemoglobin SC disease recapitulates characteristic human pathologiesJinbin Zhai, James B Papizan, Yu Yao, et al.Blood Advances|November 8, 2019
Genome editing of HBG1 and HBG2 to induce fetal hemoglobinJean-Yves Métais, Phillip A Doerfler, Thiyagaraj Mayuranathan, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2025
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled TrialYang-Si Li, Qitao Yu, Qing Bu, et al.Signal Transduction and Targeted Therapy|June 29, 2023
Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II TrialShun Lu, Hongming Pan, Lin Wu, et al.Nature Genetics|July 3, 2023
Potent and uniform fetal hemoglobin induction via base editingThiyagaraj Mayuranathan, Gregory A Newby, Ruopeng Feng, et al.Cancer Communications (London, England)|March 13, 2026
Vebreltinib for Previously Treated Astrocytoma, IDH-Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1-MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label TrialZhaoshi Bao, Yake Xue, Yanhui Liu, et al.Lancet (London, England)|May 29, 2026
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trialAnwen Xiong, Wenxiu Yao, Wei Zheng, et al.Nature|June 3, 2021
Base editing of haematopoietic stem cells rescues sickle cell disease in miceGregory A Newby, Jonathan S Yen, Kaitly J Woodard, et al.Pageof 156